Biogen Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Christopher A. Viehbacher
- Full Time Employees
- 7,500
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 225 Binney Street Cambridge MA United States 02142
- IPO Date
- Sep 17, 1991
- CIK
- 0000875045
- Website
- biogen.com
- Similar Companies
- Business
- Biogen Inc. (BIIB) discovers, develops, manufactures and commercializes therapies for neurological and neurodegenerative diseases, hemophilia, multiple sclerosis (MS), spinal muscular atrophy (SMA), lupus and rare diseases worldwide; core products include Tecfidera and Vumerity (dimethyl and diroximel fumarate) for MS, Avonex (interferon beta-1a), Plegridy (peginterferon beta-1a) and Tysabri (natalizumab) for relapsing MS, Spinraza for SMA, Leqembi for Alzheimer's disease, Skyclarys for Friedreich's ataxia and anti-CD20 therapies such as Rituxan and Gazyva for certain B-cell malignancies and autoimmune conditions. The company, founded in 1978 and headquartered in Cambridge, Massachusetts, operates in the United States, Europe, Asia and other international markets. Recent developments include the completion of its acquisition of Alcyone Therapeutics in November 2025 to bolster rare disease capabilities, a November 2025 collaboration with Dayra Therapeutics featuring a $50 million upfront payment for oral macrocyclic peptides targeting immunology, a February 2025 R&D funding agreement with Royalty Pharma worth up to $250 million for Phase 3 litifilimab in lupus, expansion of Leqembi with U.S. approval of the IQLIK subcutaneous formulation, an agreement to acquire Sage Therapeutics and groundbreaking in September 2025 for a new 580,000-square-foot headquarters at 75 Broadway set for completion in 2028 coinciding with the company's 50th anniversary.
Company News
Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2026 Business and Financial Updates
Biogen Q3 Earnings Preview: Grounds For Optimism, But Disappointment The Norm
Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
A Look at Biogen Inc (BIIB) After 4.1% Gain -- GF Value $202.16 vs Price $243.10
4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch Now
Biogen Inc. $BIIB Shares Acquired by CWA Asset Management Group LLC
Biogen to Present New Data Across Nephrology Portfolio, Including Long-term EMPAVELI® (pegcetacoplan) Phase 3 Results, at American Society of Nephrology (ASN) Kidney Week
Biogen: The Bull Case Is Extending Beyond Alzheimer's (Rating Upgrade)
3 Big Names Enjoying Renewed Analyst Backing
Here Are Monday’s Top Wall Street Analyst Research Calls: Adobe, Biogen, First Solar, GoDaddy, Hubspot, Palantir Technologies, Robinhood Markets, Snowflake, TeraWulf, T-Mobile US and More
Which Healthcare ETF Is the Better Buy: Fidelity’s Broad FHLC or Invesco’s Biotech-Focused PBE?
Stock Picks From Seeking Alpha's September 2026 New Analysts
Biogen expected to slightly beat third-quarter earnings as lupus trial data loom, Jefferies says
Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report?
Stoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S. NDA for Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome
Biogen's experimental lupus drug shows benefit against skin symptoms
Biogen's Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus
Biogen (NASDAQ:BIIB) Reaches New 12-Month High – Still a Buy?
Can Biogen's Growth Portfolio Maintain Its Lead Over Legacy MS Drugs?
4 Alzheimer's Drug Stocks to Watch on World Alzheimer's Day